This intra-individual head-to-head pilot study reveals that [161Tb]Tb-PSMA-617 delivers markedly higher tumor-absorbed doses compared to [177Lu]Lu-PSMA-617, whereas the absorbed doses of the relevant organs at risk were only slightly higher. Here, FOLH1 is linked to neoplasm.